Unitree Slump Tests China Robot IPO Boom
Unitree Robotics’ volatile Shanghai debut has prompted Chinese regulators to slow parts of the humanoid-robot IPO pipeline as they examine whether high valuations and revenue linked to government-backed projects reflect sustainable commercial demand.
Unitree became the first mainland-listed humanoid-robot manufacturer when its shares began trading on Shanghai’s STAR Market on 19 August. The company priced its IPO at 150.80 yuan per share, raising about 6.1 billion yuan and entering the market at a valuation of roughly 61 billion yuan. Its shares rose more than fivefold on their first trading day before subsequently falling about 55% from their peak.
People familiar with the regulatory process told Reuters that the volatility helped trigger tighter scrutiny of other humanoid-robot companies seeking listings. Regulators have used informal “window guidance” to hold back some proposed IPOs while reviewing valuations, commercial deployment and the quality of reported revenue. The China Securities Regulatory Commission did not respond to Reuters’ request for comment, and the action has not been announced as a formal ban on robot-company listings.
At least half a dozen Chinese humanoid-robot companies are preparing to go public, with Deep Robotics, X Square Robot and AGIBOT among those identified by Reuters. The scrutiny is increasingly focused on whether revenue comes from repeatable commercial demand or from projects supported by local authorities.
Robot data-collection centres and government-backed joint ventures have generated significant revenue for some companies. Reuters reported that local governments can provide 80% to 90% of the initial investment in some joint ventures, creating orders that can help companies build revenue and meet listing requirements. Regulators are questioning how much of that business would continue without public-sector support.
One person close to humanoid-robot investors told Reuters that valuations at some companies could fall by 60% to 70% if revenue associated with data-collection centres were excluded. That estimate is not a regulatory calculation, but it highlights the extent to which revenue quality has become central to the valuation debate.
The increased caution does not represent a withdrawal of Chinese government support for humanoid robotics. In June, the Ministry of Industry and Information Technology and the State-owned Assets Supervision and Administration Commission launched a programme aimed at accelerating real-world deployment of humanoid robots and embodied AI. The initiative targets more than 100 high-value application scenarios by the end of 2026 and aims to build deployment capacity measured in tens of thousands of units.
Shanghai has separately set targets for its embodied-intelligence industry, including more than 100 leading enterprises, 100 application scenarios and 100 internationally competitive products, with core industry output targeted above 50 billion yuan.
The shift is therefore less about whether China intends to develop a large robotics industry than about how companies entering public markets should be valued. Ruiying Zhao, senior research analyst at S&P Global Market Intelligence, described investor sentiment as moving from “blanket euphoria to selective rationality”, with greater attention being paid to whether commercial value justifies valuation premiums.
That reassessment is taking place during a broader rebound in Chinese equity fundraising. Mainland companies have raised $148.9 billion through share sales and convertible offerings so far in 2026, 59% more than during the comparable period last year, according to LSEG data cited by Reuters. Technology companies accounted for 41% of that total.
The Unitree episode shows how quickly enthusiasm for a strategically important technology can move into public-market valuation risk. Humanoid-robot companies seeking IPOs are now likely to face closer examination of deployment volumes, independent customer demand and the sustainability of revenues generated through state-supported projects.
For capital-markets investors, that places greater weight on commercial adoption rather than technical demonstrations alone. China continues to support embodied intelligence as a strategic industry, but the next round of listings may be judged more closely on whether companies can translate that support into recurring revenue and sustainable public-market valuations.
